Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect for patients undergoing cancer treatments, and ...
Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...
Leading the Way in Specialized Diabetic Foot Care in Delhi NCRDelhi, India - November 17, 2024 — Diabetes, often called the ...
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...
If you experience severe or sudden calf pain or suddenly have trouble moving or walking, it’s time to contact a healthcare ...
Scientists have designed a groundbreaking painkiller that activates solely at chronic pain sites, offering targeted, ...
During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...
The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, ...
2d
Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...
Medical Xpress on MSN3d
Cholesterol may not be the only lipid involved in trans fat-driven cardiovascular diseaseSphingolipids have become useful biomarkers for diseases like ASCVD, non-alcoholic fatty liver disease, obesity, diabetes, ...
Detailed price information for Neurometrix Inc (NURO-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback